MedTrace Logo

Gender Difference in NET Activation in Patients With Congenital Heart Disease and Heart Failure

NCT05263843 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-01-09

No results posted yet for this study

Summary

Neutrophil hyperactivation has detrimental effects on cardiac tissue after injuries, leading to fibrosis lesions and cardiac dysfunction. It is now well-established that women present with different clinical symptoms in cardiovascular disease compared to men. A cardioprotective effect in women has been suggested in some studies including patients with congenital heart disease (CHD) and heart failure. Our hypothesis is that estrogen protects the hearts of female patients aged 18-45 with CHD. There is no information available as to the involvement of neutrophils in heart failure in females compared to male patients, and therefore this study will provide important information for both the CHD and neutrophil biology fields comparing NET activation in women and men with severe CHD.

Conditions

Interventions

DIAGNOSTIC_TEST

Biological markers of myocardial fibrosis

Blood sample for measurements of NET activation and collagen biomarkers

Sponsors & Collaborators

  • National Research Agency, France

    collaborator OTHER

  • European Commission

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Magalie Ladouceur, Pr · Hôpital Européen Georges-Pompidou

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-22
Primary Completion
2025-02-23
Completion
2025-02-23

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05263843 on ClinicalTrials.gov